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Rationale 
 
 
 
Magnitude of genomic derangement 
?? 
Lawrence MS, et al. Nature 499: 214-218, 2013 
Govindan, et al. Cell 150: 1121, 2012 
Drugable targets in smokers and never smokers 
Nature 489:519-525, 2012 
Significantly mutated genes in squamous NSCLC 
Evolution of NSCLC, 
from histology to molecular characteristics 
Li T, et al. JCO, 2013 
Lung cancer 
Willam Coley (1862 – 1936) 
Role of the immune system in cancer and the process of 
immunoediting 
Equilibrium Escape Elimination 
• Effective antigen 
processing/presentation 
• Effective activation and 
function of effector cells 
‒ e.g., T-cell activation 
without co-inhibitory 
signals 
Tumour cells 
Normal cells 
• Tumours avoid elimination 
through the outgrowth of 
tumour cells that can suppress, 
disrupt, or ‗escape‘ the immune 
system 
Treg 
Immunoediting describes the contrasting role of the immune system in protecting 
against tumour development and promoting tumour growth 
• Genetic instability 
• Tumour heterogeneity 
• Immune selection 
Cancer immunosurveillance Cancer dormancy Cancer progression 
CD8+  
T cell 
CD4+  
T cell NK cell 
Vesely MD, et al. Ann Rev Immunol 29:235-271, 2011 
T-cell based immunomodulation 
Tartour E, et al. Lancet Respir Med 1:551-563, 2013 
1. Dieu-Nosjean MC, et al. J Clin Oncol 2008;26:4410–4117; 2. Petersen RP, et al. Cancer 2006;107:2866–2872; 3. Al-Shibli K, et al. 
APMIS 2010;118:371–382; 4. Ruffini E, et al. Ann Thorac Surg 2009;87:356–372; 5. Zhuang X, et al. Appl Immunohistochem Mol 
Morphol 2010;18:24–28; 6. Hiraoka K, et al. Br J Cancer 2006;94:275–280; 7. Kawai O, et al. Cancer 2008;113:1387–1395; 8. McCoy 
MJ, et al. Br J Cancer 2012;107:1107–1115; 9. Wakabayashi O, et al. Cancer Sci 2003;11:1003–1009; 10. Tao H, et al. Lung Cancer 
2012;75:95–101; 11. Shimizu K, et al. J Thorac Oncol 2010;5:585–590; 12. Jin J, et al. PLoS One 2013;8:e61024 
Prognostic roles of immune cells in NSCLC 
Dendritic cells 
Favourable prognosis1 
OS, DSS, and DFS 
CD3+ cells 
Favourable prognosis2–4 
DSS, lower risk of disease recurrence 
CD8+ cells 
Favourable prognosis5–8: OS 
CD4+ cells 
Favourable prognosis6,9: OS 
Macrophages 
Favourable prognosis7: OS 
Tregs 
Unfavourable prognosis10,11:  
OS, relapse- and recurrence-free survival 
NK cells 
Unfavourable prognosis12: PD 
• Similar to melanoma and RCC, lung tumours are recognised 
by the immune system, and initiate an immune response 
• Certain immune cells are associated with a better 
prognosis/improved outcome, while others suggest  
an unfavourable prognosis and disease outcome 
Tumour 
The T-cell antitumour response 
Andersen MH, et al. J Invest Dermatol 126:32–41, 2006; Pardoll DM. Nat Rev Cancer 11:252–264, 2012; 
Mellman I, et al. Nature 480:480–489, 2011; Heemskerk B, et al. EMBO J 32:194–203, 2013; Boudreau JE, et al. Mol Ther 19:841–853, 2011; 
Janeway CA, et al. Immunobiology: The Immune System in Health and Disease. 6th ed. New York, NY: Garland Science; 2004 
Tumour antigens  
released by 
tumour cells 
Tumour antigens  
presented to T cells 
T cells are 
activated and  
proliferate 
T cells recognize  
tumour antigens 
T cells kill  
tumour cells 
1 
4 
2 
3 
5 
APC = antigen-presenting cell 
Regulating the T-cell immune response 
 T cell responses are regulated 
through a complex balance of 
inhibitory (‗checkpoint‘) and 
activating signals 
 Tumours can dysregulate 
checkpoint and activating 
pathways, and consequently 
the immune response 
 Targeting checkpoint and 
activating pathways is an 
evolving approach to cancer 
therapy, designed to promote an 
immune response 
PD-1 
CTLA-4 
Inhibitory receptors Activating receptors 
TIM-3 
LAG-3 
Antagonistic 
(blocking) 
antibodies 
Agonistic antibodies 
T cell stimulation 
CD28 
OX40 
CD137 
aThe image shows only a selection of the receptors/pathways involved 
LAG-3 = lymphocyte-activation gene 3 
Adapted from Mellman I, et al. Nature 480:481–489, 2011; Pardoll DM. Nat Rev Cancer 12:252–264, 2012 
Multiple interactions regulate T-cell responses 
Pardoll DM. Nature Rev Cancer 12:252-264, 2012 
Tumours use various mechanisms to escape the 
immune system 
Immune escape mechanisms are complex and frequently overlapping 
 
Davies M, et al. Cancer Management and Research 6:63-75, 2014 
aCovers correlation with improved overall or progression-free survival, disease stage, or therapy outcome 
bThe type of lymphocyte dictates where there is a correlation with improved or worsened outcome 
cBased on PubMed search conducted in October 2013 using the terms ‗spontaneous regression‘ and the tumour type 
 
1. Hiraoka K, et al. Br J Cancer. 2006;94:275–280; 2. Galon J, et al. Science. 2006;29:1960–1964; 3. Mahmoud SM, et al. J Clin Oncol. 
2011;29:1949–1955; 4. Loi S, et al. J Clin Oncol. 2013;31:860–867; 5. Piras F, et al. Cancer. 2005;104:1246–1254; 6. Azimi F, et al. J Clin Oncol. 
2012;30:2678–2683; 7. Siddiqui SA, et al. Clin Cancer Res. 2007;13:2075–2081; 8. Donskov F, et al. Br J Cancer. 2002;87:194–201; 9. Flammiger 
A, et al. APMIS. 2012;120:901–908; 10. Zhang L, et al. N Engl J Med. 2003;348:203–213; 11. Badoual C, et al. Clin Cancer Res. 2006;12:465–472; 
12. Piersma SJ, et al. Cancer Res. 2007;67:354–361; 13. Nakamura Y, et al. Lung Cancer. 2009;65:119–122; 14. Bir AS, et al. Anticancer Res. 
2009;29:465–468; 15. Kalialis LV, et al. Melanoma Res. 2009;19:275–282; 16. Kawai K, et al. Int J Urol. 2004;11:1130–1132; 17. Kumar T, et al. 
Respir Med. 2010;104:1543–1550; 18. Øvestad IT, et al. Mod Pathol. 2010;23:1231–1240; 19. Castle PE, et al. Obstet Gynecol. 2009;113:18–25 
Tumour type 
Prognostica tumour  
infiltrating lymphocytesb 
Immune-related  
spontaneous tumour 
regressionc 
NSCLC Yes1 Yes13 (rare) 
CRC Yes2 Yes14 
Breast Yes3,4 No 
Melanoma Yes5,6 Yes15 
Renal Yes7,8 Yes16,17 
Prostate Yes9 No 
Ovarian Yes10 No 
Head and neck Yes11 No 
Cervical Yes12 
Evidence for cervical 
intraepithelial neoplasia 2/318,19 
Data suggesting immune recognition and response in 
selected tumour types 
Potential investigational immunotherapeutic approaches 
as treatment options for lung cancer 
CTLA-4 = cytotoxic T-lymphocyte antigen-4; PD-1 = programmed death-1; PD-L1 = programmed death ligand-1 
www.clinicaltrials.gov accessed 26 March 2014; NCCN Guidelines®. NSCLC. V2.2013; Peters S, et al. Ann Oncol. 2012;23:vii56–vii64  
Therapeutic  
vaccines 
Enhancing  
immune  
cell function 
Adoptive 
Antitumour  
mAbs 
Bavituximab  
EGFR inhibition 
Adoptive  
cell transfer 
Modulate T-cell 
function 
Cytokines 
GSK1572932A 
TG4010 
Belagenpumatucel-L 
Tergenpumatucel-L 
Racotumomab 
Stimuvax 
CIMAvax 
Immuno-Oncology 
(I-O) 
CTLA-4 inhibition 
PD-1 inhibition 
PD-L1 inhibition 
Passive (adoptive) 
Designed to act at tumour;  
immune-based mechanism 
Active 
Designed to act on the immune system itself 
Immunotherapy 
Antigen 
dependent 
Antigen 
independent 
NSCLC tumor immunology and modulation by 
conventional therapies 
Champiat S, et al. J Thorac Oncol 9:144-153, 2014 
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Vaccines 
 
 
 
Drake GC, et al. Nat Rev Clin Oncol 11:24–37, 2014 
Mechanism of action of cancer vaccines 
Winter H, et al. J Thorac Dis 3:105–114, 2011 
Mechanism of action of cancer vaccines 
Tucker ZC, et al. Cancer Treat Rev 38:650–661, 2012 
Monovalent vaccine clinical trials in NSCLC 
Tucker ZC, et al. Cancer Treat Rev 38:650–661, 2012 
Multivalent vaccine clinical trials in NSCLC 
Drake GC, et al. Nat Rev Clin Oncol 11:24–37, 2014 
Phase II and III vaccine trials in NSCLC 
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CTLA-4 
 
 
 
Ribas A, et al. N Engl J Med 366:2517–2519, 2012 
Differences in CTLA-4 and PD-1 blockade 
T cell 
Tumour cell 
MHC 
TCR 
PD-L1 PD-1 
- - - 
T cell 
Dendritic 
cell 
MHC 
TCR 
CD28 
B7 CTLA-4 
- - - 
Activation 
(cytokines, lysis, proliferation,  
migration to tumour) 
B7 
+ + + 
+ + + 
anti-CTLA-4 
 
anti-PD-1 
Tumour microenvironment  
+ + + 
PD-L2 PD-1 
anti-PD-1 
 
- - - 
PD-1 blockade (nivolumab)  CTLA-4 blockade (ipilimumab)  
Adapted from Weber J. Cancer Immunol Immunother 58:823, 2009 
Ipilimumab blocks CTLA-4 and augments T-cell 
activation 
T cell 
TCR 
CTLA-4 
APC 
MHC 
B7 
T-cell  
inhibition 
T cell 
TCR 
CTLA-4 
APC 
MHC B7 
T-cell  
activation 
T cell 
TCR 
CTLA-4 
APC 
MHC B7 
T-cell  
potentiation 
Ipilimumab 
blocks 
CTLA-4 
CD28 CD28 
Randomized phase II study of Ipilimumab and CT in 
advanced NSCLC 
Lynch TJ ,et al. J Clin Oncol 30:2046-2054, 2012 
 Primary endpoint: irPFS 
 Cx regimen: Pac 175 mg/m2/carbo AUC 6 prior to start of ipilimumab (10 mg/kg) 
Concurrent 
IPI + Pac/Carbo 
Phased 
IPI + Pac/Carbo 
Control 
P + Pac/Carbo 
(N = 204) 
R
a
n
d
o
m
iz
e
 
First-line 
Stage lllb/IV NSCLC 
18 yrs of age or older 
ECOG PS 0/1 1:1:1 
Induction Phase 
(n = 203) 
Maintenance Phase 
(n = 73) 
q3w q12w 
C C C C C C 
Follow-up 
phase 
IPI IPI IPI IPI P P 
IPI IPI 
C C C C C C 
Follow-up 
phase 
IPI IPI IPI IPI P P 
IPI IPI 
C C C C C C 
Follow-up 
phase 
P P P P P P 
P P 
Lynch TJ, et al. J Clin Oncol 30:2046-2054, 2012 
Randomized phase II study of Ipilimumab and CT in 
advanced NSCLC 
Lynch TJ, et al. J Clin Oncol 30:2046-2054, 2012 
Randomized phase II study of Ipilimumab and CT in 
advanced NSCLC 
ClinicalTrials.gov. NCT01285609  
Ongoing phase III: Ipilimumab in squamous NSCLC 
 Double-blind study 
 Primary endpoint: OS 
 Secondary endpoints: OS in patients who receive 1 dose of ipilimumab/ placebo, PFS, RR 
Stage IV or 
recurrent 
squamous cell 
NSCLC 
ECOG PS ≤ 1 
(N = 1100) 
 
Carboplatin AUC 6 + 
Paclitaxel 175 mg/m2 q3w x 6 +  
Placebo  
 
 
Carboplatin AUC 6 + 
Paclitaxel 175 mg/m2 q3w x 6 +  
Ipilimumab 10 mg/kg q3w x 4, then  
q12w starting at Wk 24 
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PD-1 & PD-L1 
 
 
 
Sznol M, et al. Clin Cancer Res. 19:1021-1034, 2013 
Blockade of PD-1 binding to PDL1 (B7-H1) and PDL-2 
(B7-DC) revives T cells 
PD-L2-mediated 
inhibition of TH2 T cells 
Stromal PD-L1 
modulation of T cells 
 PD-L1 expression on tumor 
cells is induced by γ-
interferon 
 In other words, activated T 
cells that could kill tumors 
are specifically disabled by 
those tumors 
PD-1 
PD-L1 
PD-L2 
T-cell receptor  
MHC-1 
CD28 
Shp-2 
B7.1 
IFN-γ-mediated 
upregulation of 
tumor PD-L1 
PD-L1/PD-1–mediated 
inhibition of tumor cell killing 
Priming and 
activation of  
T cells 
Immune cell  
modulation of T cells 
Tumor Cell 
IFN-γR 
IFN-γ 
Tumor-associated 
fibroblast M2 
macrophage 
Treg  
cell 
Th2  
T cell 
Other NFκB P13K 
CD8+ cytoxic 
T lymphocyte 
T-cell polarization 
TGF-β 
IL-4/13 
Can you generate  
tumor-killing T cells? 
Dendritic  
Cell 
Antigen priming 
Can the T cells  
get to the tumor? 
T-cell trafficking 
Can the T cells  
see the tumor? 
Peptide-MHC 
expression 
Can the T cells  
be turned off? 
Inhibitory cytokines 
Can the T cells  
be turned off? 
PD-L1 expression  
on tumor cells 
Ribas A, et al. N Engl J Med 366:2517–2519, 2012 
Role of PD-1 pathway in suppressing antitumour 
immunity 
MHC 
PD-L1 
PD-1 PD-1 
PD-1 PD-1 
Nivolumab is a PD-1 receptor blocking antibody 
Recognition of tumour by T cell through 
MHC/antigen interaction mediates IFNγ release 
and PD-L1/2 upregulation on tumour 
Priming and activation of T cells through 
MHC/antigen and CD28/B7 interactions with 
antigen-presenting cells 
T-cell 
receptor 
T-cell 
receptor 
PD-L1 
PD-L2 
PD-L2 
MHC 
CD28 B7 
T cell 
NFκB 
Other 
PI3K 
Dendritic 
cell Tumour cell 
IFNγ 
IFNγR 
Shp-2 
Shp-2 
Somme immune checkpoint inhibitors in NSCLC 
Champiat S, et al. J Thorac Oncol 9:144-153, 2014 
Brahmer JR, et al. ASCO 2013. Abstract 8030 
Nivolumab phase I trial in squamous/nonsquamous NSCLC 
Adapted from Brahmer JR, et al. Mini-Oral presentation at WCLC 2013. J Thorac Oncol. 2013;8(suppl 2):abstract: MO18.03 
Duration of response and overall survival with 
nivolumab monotherapy in NSCLC 
NSCLC respondersa,b by histology 
Time (week) Months since initiation of treatment 
129 111 82 66 48 35 31 28 20 9 4 3 3 3 2 1 1 1 0 0 
Subjects at risk 
All treated subjects with NSCLC 
Median OS: 9.9 months (7.8, 12.4) 
1 year OS rate 42%  
(48 patients at risk) 
2 year OS rate 24%  
(20 patients at risk) 
Vertical line at 96 weeks = maximum duration of continuous nivolumab therapy 
aResponses were assessed by modified RECIST v1.0 
bAll efficacy analyses based on data collected as of September 2013  
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Duration of response 
on study 
Ongoing 
response 
Time to response 
Response duration 
after discontinuation 
Died/treated Median (95% CI) 
94/129 9.90 (7.80,12.40) 
Brahmer JR, et al. ASCO 2013. Abstract 8030 
Nivolumab: activity across NSCLC histology 
 
NSCLC histology 
 
Dose (mg/kg) 
 
ORR % (n/N) 
Stable disease rate 
≥24 week, % (n/N) 
Squamous 
All doses 16.7 (9/54) 14.8 (8/54) 
1 0 (0/18) 26.7 (4/15) 
3 22.2 (4/18)  5.6 (1/18)  
10 23.8 (5/21)  14.3 (3/21) 
 
 
 
Nonsquamous 
All doses 17.6 (13/74) 6.8 (5/74) 
1 5.6 (1/18) 5.6 (1/18) 
3 26.3 (5/19) 10.5 (2/19) 
10 18.9 (7/37) 5.4 (2/37) 
Adapted from Brahmer JR, et al. Mini-Oral presentation at WCLC 2013. J Thorac Oncol. 2013;8(suppl 2):abstract: MO18.03 
Selected adverse events (≥1%) in patients with NSCLC 
treated with nivolumab 
• Select adverse event defined as an event with potential immunological aetiologies that require 
more frequent monitoring and/or unique intervention 
• All patients have ≥1 year of follow-up 
• Drug-related pneumonitis (any grade) occurred in 8 NSCLC patients (6%); 
3 patients (2%) had grade 3-4 pneumonitis of which 2 cases were fatal 
 
 
Patients, n (%)    N=129 
Any grade Grade 3/4 
Any treatment-related select adverse event 41 (53) 5 (6)  
Skin 16 (20) 0 
Gastrointestinal 12 (15) 1 (1) 
Pulmonary 7 (9) 2 (3) 
Endocrinopathies 6 (8) 0 
Hepatic 5 (6) 1 (1) 
Infusion reaction 4 (5) 1 (1) 
Renal 3 (4) 0 
Nivolumab: change in tumour burden and response 
kinetics by number of prior therapies 
Dashed horizontal lines denote 30% decrease for PR (in the absence of new lesions) and 20% increase for PD per RECIST v1.0 
Adapted from Gettinger S, et al. Poster presentation at WCLC 2013. J Thorac Oncol. 2013;8(suppl 2):abstract: P2.11-038 
Nivolumab: change in tumour burden according to EGFR 
and KRAS mutation status 
Dashed horizontal lines denote 30% decrease for PR (in the absence of new lesions) and 20% increase for PD per RECIST v1.0 
Adapted from Gettinger S, et al. Poster presentation at WCLC 2013. J Thorac Oncol. 2013;8(suppl 2):abstract: P2.11-038 
Nivolumab plus CT: change in tumour burden 
Baseline tumour measurements are standardised to zero; tumour burden is measured as the sum of the longest diameters of 
target lesions 
Horizontal lines denote 30% decrease for PR and 20% increase for PD per RECIST 1.1 Only patients with both baseline and on-
study target lesion measurements are included 
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Patient 
Rizvi NA, et al. ASCO 2013. Abstract 8072 
Nivolumab plus CT: duration of response 
Rizvi NA, et al. ASCO 2013. Abstract 8072 
Nivolumab  
(10 mg/kg) 
Nivolumab 
 (5 mg/kg) 
Gem/Cis 
n=12 
(Arm A) 
Pem/Cis 
n=15 
(Arm B) 
Pac/Carb 
n=15 
(Arm C) 
Pac/Carb 
n=14 
(Arm C5)a 
Number of responders, n 4 7 7 7 
Ongoing responders, n (%) 2 (50) 2 (29) 2 (29) 5 (71) 
Estimated median duration of 
response,b,c weeks 
NR  25 26 22 
Response durationd 12/18/ 
33+/36+ 
13/14+/ 
18+/18/ 
25/32/38 
11+/12/14/ 
24/27/29/ 
39+ 
11/12+/16+/17+/ 
22+/22/24+ 
Carb = carboplatin; Cis = cisplatin; Gem = gemcitabine; Pac = paclitaxel; Pem = pemetrexed 
aProtocol was amended to include an extra arm for this combination;  
bTime from first response to documented progression, death, or last tumour assessment; 
cEstimated mean duration determined by Kaplan-Meier curves; 
d+indicates ongoing response 
 
Nivolumab plus CT: duration of response 
Rizvi NA, et al. ASCO 2013. Abstract 8072 
Nivolumab  
(10 mg/kg) 
Nivolumab 
 (5 mg/kg) 
 
 
Treatment-related AE, n (%) 
Gem/Cis 
n=12 
(Arm A) 
Pem/Cis 
n=15 
(Arm B) 
Pac/Carb 
n=15 
(Arm C) 
Pac/Carb 
n=14 
(Arm C5)a 
Total 
 
N=56 
Any AE 0 5 (33) 3 (20) 4 (29) 12 (21) 
Pneumonitis 0 2 (13) 0 2 (14) 4 (7) 
Acute renal failure 0 1 (7) 0 2 (14) 3 (5) 
Hypersensitivity 0 1 (7) 2 (13) 0 3 (5) 
Colitis 0 1 (7) 1 (7) 0 2 (4) 
Carb = carboplatin; Cis = cisplatin; Gem = gemcitabine; Pac = paclitaxel; Pem = pemetrexed 
aProtocol was amended to include an extra arm for this combination 
ClinicalTrials.gov. NCT01642004  
Ongoing phase III: Nivolumab in squamous NSCLC 
 Primary endpoints: ORR, OS 
 Secondary endpoints: PFS, ORR, and OS in PD-L1–positive vs PD-L1–negative subgroups, duration 
of OR, time to OR, proportion of patients exhibiting disease-related symptom progression as per 
Lung Cancer Symptom Scale 
Stage IIIB/IV or 
recurrent  
squamous-cell 
NSCLC following RT 
or resection, 
 previous Pt-
containing 
chemotherapy 
ECOG PS ≤ 1 
(N = 264) 
Treat until 
progression or  
unacceptable 
toxicity or  
withdrawal of 
consent  
Docetaxel 75 mg/m2 IV q3w 
Nivolumab 3 mg/kg IV q2w 
Nivolumab development in NSCLC 
Setting Population Study Design Endpoint Status 
1st-line 
 
 
 
Treatment-naïve  
 
 
CA209-012 
(phase 1) 
 
 
Nivolumab monotherapy; 
nivolumab combined with 
platinum doublets; erlotinib; 
bevacizumab or ipilimumab 
Safety;  
antitumour 
activity 
 
Ongoing 
 
 
 
Treatment-naïve  
 
CA209-026 
(phase 3) 
Nivolumab vs investigator‘s 
choice of chemotherapy 
 PFS in high 
PD-L1 
expression 
tumours 
Not yet 
recruiting 
2nd-line 
Prior platinum, 
squamous 
histology 
CA209-017 
(phase 3) 
 
Nivolumab vs docetaxel 
 
 
ORR/OS 
 
 
Ongoing/ 
Accrual 
complete 
 
 
Prior platinum, 
nonsquamous 
histology 
CA209-057 
(phase 3) 
 
Nivolumab vs docetaxel 
 
 
OS 
 
 
Ongoing/ 
Accrual 
complete 
 
 
3rd-line 
and 
beyond 
 
Squamous 
histology,  
≥2 prior 
treatments 
CA209-063 
(phase 2) 
 
 
Nivolumab monotherapy 
 
 
 
ORR 
 
 
Ongoing/ 
Accrual 
complete 
 
 
www.clinicaltrials.gov 
CA209-012/NCT01454102: ARMS A-F 
Phase 1 trial: chemotherapy-based arms 
 Stage IIIB/IV NSCLC 
N=220 (across all arms of trial)  
Until PD or discontinuation due to toxicity 
ARM A 
Squamous 
NSCLC 
 
Cis 75 mg/m2 IV 
D1 Q3W x four 
cycles 
 
Gem 1250 mg/m2 
IV 
D1 and D8  
Q3W x four 
cycles 
 
Nivolumab  
10 mg/kg 
D1 Q3W 
ARM B 
Nonsquamous 
NSCLC 
 
Cis 75 mg/m2 IV 
D1 Q3W x four 
cycles 
 
Pem 500 mg/m2 
IV D1 Q3W x four 
cycles 
 
 
Nivolumab  
10 mg/kg 
D1 Q3W 
ARM C 
Any histology 
 
Carbo AUC 6 IV 
 D1 Q3W x four 
cycles 
 
Pac 200 mg/m2 IV 
D1 Q3W x four 
cycles  
 
 
Nivolumab  
10 mg/kg 
 D1 Q3W 
ARM D 
Nonsquamous 
NSCLC 
≥4 cycles of 
platinum-doublet 
without PD 
 
Maintenance: 
Bev 15 mg/kg IV  
D1 Q3W  
until PD or    
discontinuation 
due to toxicity 
 
Nivolumab  
5 mg/kg IV  
D1 Q3W 
ARM E 
Nonsquamous 
NSCLC with 
EGFR mutation 
 
 
Erl 150 mg/day 
PO until PD or 
discontinuation 
due to toxicity  
 
 
Nivolumab  
3 mg/kg IV  
D1 Q2W 
ARM F 
Any histology 
 
 
 
 
 
 
 
 
 
 
Nivolumab  
3 mg/kg IV  
Q2W 
Protocol was amended to include Arm C5 to obtain further information regarding clinical safety and activity of nivolumab at 
5 mg/kg in combination with paclitaxel and carboplatin. 
www.clinicaltrials.gov 
CA209-012/NCT01454102: ARMS G-M 
Phase 1 trial: chemotherapy-based arms 
 Stage IIIB/IV NSCLC 
N=220 (across all arms of trial)  
Until PD or discontinuation due to toxicity 
ARM G 
Squamous 
NSCLC 
 
IPI 3 mg/kg  
D1 Q3W x 4 
 
Nivolumab  
1 mg/kg IV  
D1 Q3W x 4, 
then 3 mg/kg 
Q2W 
ARM H 
Nonsquamous 
NSCLC 
 
IPI 3 mg/kg  
D1 Q3W x 4 
 
Nivolumab  
1 mg/kg IV  
D1 Q3W x 4, 
then 3 mg/kg 
Q2W 
ARM I 
Squamous 
NSCLC 
 
IPI 1 mg/kg  
D1 Q3W x 4 
 
Nivolumab  
3 mg/kg IV  
D1 Q3W x 4, 
then 3 mg/kg 
Q2W 
ARM J 
Nonsquamous 
NSCLC 
 
IPI 1 mg/kg  
D1 Q3W x 4 
 
Nivolumab  
3 mg/kg IV  
D1 Q3W x 4, 
then 3 mg/kg 
Q2W 
ARM K 
Squamous 
NSCLC  
pts completing  
≥4 cycles of 
platinum-
doublet 
chemotherapy  
 without PD 
 
Switch 
maintenance 
nivolumab  
3 mg/kg IV 
Q2W  
 
 
ARM L 
Nonsquamous 
NSCLC 
patients 
completing  
≥4 cycles of 
platinum-
doublet 
chemotherapy  
(
 
 bev) without 
PD 
 
Switch 
maintenance 
nivolumab  
 3 mg/kg IV 
Q2W 
ARM M 
Any histology 
patients with 
untreated, 
asymptomatic 
brain 
metastases 
 
 
Nivolumab  
3 mg/kg IV 
Q2W 
 
 
IASLC, 15th WCLC, abst 2416, 2013  
Lambrolizumab (MK-3475) in 2nd line for NSCLC 
Objectives of Protocol: 
 Assess safety and efficacy in patients with previously treated NSCLC 
 
Eligibility Criteria for Protocol: 
 2 prior systemic therapies 
 ≥1 measurable lesion 
 ECOG PS of 0-1 
 Submission of a new tumor specimen for PD-L1 analysis 
 
Treatment: 10 mg/kg IV Q3W until progression by irRC, intolerable toxicity, or consent withdrawal 
 
Patients:  N = 38: 42% male, 45% aged ≥65 years, 58% with ECOG PS 1,  
66% former/current smokers, 16% squamous, 11% treated brain metastases 
 
PD-L1 Status:  Assessed with a Merck proprietary IHC clinical trial assay; 61% positive (>0),  
26% negative, 13% not evaluable; potential cut point determined by the Youden Index from 
a receiver operator characteristics curve 
IASLC, 15th WCLC, abst 2416, 2013  
Lambrolizumab (MK-3475) in 2nd line for NSCLC 
Subgroup 
irRC, Investigator Review RECIST v1.1, Independent Review 
Median OS, wk (95% 
CI) N 
ORR, n (%) 
[95% CI] 
Median PFS, wk 
(95% CI) N 
ORR,* (%),  
[95% CI] 
Median PFS, wk 
(95% CI) 
All 38 
9 (24%)  
[11%, 40%] 
9.1  
(8.3, 17.4) 
33 
7 (21%)  
[9%, 39%] 
9.7  
(7.6, 17) 
51  
(14, NR) 
Non-squamous 31 
7 (23%)  
[10%, 41%] 
9.1  
(8.3, 17.0) 
26 
4 (16%)  
[4%, 35%] 
10.3  
(7.6, 17) 
35  
(14, NR) 
Squamous 6 
2 (33%)  
[4%, 78%] 
23.5  
(2.7, NR) 
6 
2 (33%)  
[4%, 78%] 
15.2  
(1.4, NR) 
NR  
(2.7, NR) 
Patients with measurable disease on baseline imaging and an evaluable tumor specimen for PD-L1 
Score ≥ potential cut 
point 
9 
6 (67%)  
[30%, 93%] 
— 7 
4 (57%)  
[18%, 90%] 
— — 
Score < potential cut 
point 
24 
1 (4%)  
[0%, 21%] 
— 22 
2 (9%)  
[1%, 29%] 
— — 
0 20 40 60 80 
Time (weeks) 
AN 169 
AN 181 
AN 196 
AN 197 
AN 201 
AN 179 
AN 173 
AN 161 
AN 152 
MK-3475 Responders Have Prolonged Duration of 
Response 
On therapy 
Off therapy 
Therapy continuing 
Confirmed response 
Progression 
Horn L, et al. Mini-Oral presentation at WCLC 2013. J Thorac Oncol. 2013;8(suppl 2):abstract: MO18.01 
MPDL3280A in monotherapy in NSCLC: phase I trial 
• Response in 12/53 patients 
(ORR: 23%) 
• 3 squamous 
• 9 nonsquamous 
• PD rate: 40% (21/53) 
• Rapid and durable 
responses 
 
PD = progressive disease; ORR = objective response rate; NS = nopnsquamous; S = squamous 
aORR includes investigator assessed unconfirmed and confirmed partial responses per RECIST v1.1 
bpatients experiencing ongoing benefit per investigator 
Patients first dosed at 1-20 mg.kg by Oct 1 2012. Data cut off April 30 2013 
NS 
S 
NS 
NS 
NS 
S 
NS 
S 
NS 
NS 
NS 
NS 
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 
Time (weeks) 
On study, on treatment 
Treatment discontinued 
Ongoing response 
First response 
On study, post treatment 
First PD 
O
R
R
 (
%
) 
EGFR 
mutation  
EGFR 
wildtype 
Horn L, et al. Mini-Oral presentation at WCLC 2013. J Thorac Oncol. 2013;8(suppl 2):abstract: MO18.01 
MPDL3280A: activity across NSCLC patient subgroups 
 EGFR status (n=53) 
– EGFR mutation positive: 11%; EGFR wildtype: 76%; Unknown: 13% 
 KRAS status (n=53) 
– KRAS mutation positive: 19%; KRAS wildtype: 51%; Unknown: 30% 
 
KRAS 
mutation  
KRAS 
wildtype 
30% 
8/27 
10% 
1/10 
23% 
9/40 17% 
1/6 O
R
R
 (
%
) 
1Brahmer, et al. IASLC WCLC, 2013 2Garon E, et al. IASLC WCLC, 2013 3 Garon E, et al. ASCO 2014 abstr 8020 
4Brahmer, et al. NEJM 2012 5Horn L, et al. IASLC WCLC ,2013 abstr MO18.01 
6Soria JC, et al. European Cancer Congress 2013 abstr 3408 
Efficacy ? 
Anti-PD-1 Nivolumab 
– 129 NSCLC pts1 – ORR 17,1%, (21,7%)* 
– 50% responded in 8 weeks 
– Median OS 9,9 months 
Anti-PD-1 MK-3475 
– 38 NSCLC pts2 – ORR 21%, (24%)* 
– 221 NSCLC pts (80% PD-L1+)3 – ORR 15%, (21%)* 
 
Anti-PD-L1 MPDL3280A 
– 175 pts5 (85 NSCLC – 53 evaluable – 85% PD-L1+) – ORR 23% 
Anti-PD-L1 BMS 936559 
– 207 pts4 (75 NSCLC – 49 evaluable) – ORR 10% 
Anti-PD-L1 MEDI4736 
– 26 pts6 (13 NSCLC) – ORR 15% 
  *including immune responders, irRECIST 
1Brahmer, et al. IASLC WCLC, 2013 2Garon E, et al. IASLC WCLC, 2013 3Brahmer, et al. NEJM 2012 
4Horn L, et al. IASLC WCLC ,2013 abstr MO18.01 5Soria JC, et al. European Cancer Congress 2013 abstr 3408 
Toxicity ? 
Anti-PD-1 Nivolumab - 129 NSCLC pts1 
 - 53% related AEs, 5% Gr 3-4 
 - Pneumonitis – 6%, Gr 3-4 3 pts (2%) – 2 deaths 
Anti-PD-1 MK-3475 - 221 NSCLC pts2  
 - 48% related AEs - fatigue, 6% Gr 3-4 
 - Pneumonitis – Gr 3-4 3 pts (1%) 
 
Anti-PD-L1 MPDL3280A - 85 NSCLC pts4  
 - 66% related AEs, 11% Gr 3-4 - fatigue 
 - No Gr 3-5 pneumonitis 
Anti-PD-L1 BMS 936559 - 207 pts4 
 - 61% related AEs, 9% Gr 3-4 
 - No pneumonitis 
Anti-PD-L1 MEDI4736 - 26 pts5 (13 NSCLC)  
 - 34% related AEs, no Gr 3-4 
 - No pneumonitis, no colitis 
American Cancer Society. Treatment types http://www.cancer.org/; Topalian SL, et al. N Eng J Med 2012;366(26):2443–2454 and oral 
presentation at ASCO 2013: J Clin Oncol 2013;31(15 suppl):abstract 3002; Hamid O, et al. N Eng J Med 2013;369:134–144; Dendreon. 
PROVENGE® Prescribing Information updated June 2011; Bristol-Myers Squibb. YERVOY (ipilimumab) REMS and Prescribing Information 
available at http://www.yervoy.com accessed November 26, 2013 
Tolerability of oncology therapies 
Different spectrum of AEs with each modality 
Chemotherapy 
 
Target 
Rapidly dividing tumour and 
normal cells  
 
Adverse events 
Diverse due to non-specific 
nature of therapy 
Targeted therapies 
 
Target 
Specific molecules involved in 
tumour growth and progression 
 
Adverse events 
Reflect targeted nature 
I-O therapies  
 
Target 
Immune system 
 
 
Adverse events 
Unique events can occur as a 
result of  immune-system activity 
Some AEs with I-O may present like those with other therapies 
Require different management strategies  
BUT – AEs may have different aetiologies 
e.g. diarrhoea/colitis, fatigue, rash/pruritus, endocrinopathies 
 
 
Predicting / Enriching for response ? 
ORR : 17,1 – 24 % 
 
 Tissue: 
  - IHC for T cells and PD-L1 
  - Gene signature for immune responsiveness, immunoscore 
 
 Blood markers, imaging 
 
 Clinical factors 
Clinical factors for response ? 
 Histology? – SCLC more likely to respond? 
  - Nivolumab 14/76 RR - 33% SCLC, 12% non-SCLC 1 
  - MK-3475 9/38 RR – 33% SCC, 23 non-SCLC 2 
 
 Smoking? Mutation status? 
  - 85 pts, with MPDL3280A 3, 4 
 
 
1Brahmer, et al. IASLC WCLC, 2013 2Garon E, et al. IASLC WCLC, 2013 
3Horn L, et al. IASLC WCLC ,2013 abstr MO18.01 4Soria JC, et al. European Cancer Congress 2013 abstr 3408 
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23% 
9/40 17% 
1/6 
Planned and ongoing lung cancer trials 
Phase Treatment Patient population Status 
Nivolumab 
1 
Plus various 
(including 
ipilimumab) 
NSCLC Recruiting 
1B Monotherapy 
Advanced or recurrent 
NSCLC 
Ongoing* 
2 Monotherapy 
Advanced or 
metastatic NSCLC 
Ongoing* 
3 Monotherapy Squamous NSCLC Ongoing* 
3 Monotherapy 
Stage IV first line or 
PDL-1+ NSCLC 
Not yet open 
3 Monotherapy 
Following platinum 
failure 
Ongoing* 
3 Monotherapy 
Advanced or 
metastatic NSCLC 
Not yet open 
Pembrolizumab 
1 
Monotherapy  
and plus 
chemotherapy  
NSCLC Recruiting 
1 Monotherapy PDL-1+ NSCLC Recruiting 
1 Monotherapy 
Locally advanced 
NSCLC 
Recruiting 
 
1/2 Combination  
Advanced or 
metastatic NSCLC 
Recruiting 
2 Monotherapy 
NSCLC and brain 
metastases 
Not yet open 
2/3 Monotherapy Prior-treated NSCLC Recruiting 
Phase Treatment Patient population Status 
Ipilimumab 
1 
Plus erlotinib or 
crizotinib 
Extensive disease 
SCLC 
Not yet open 
1 Plus chemotherapy Neoadjuvant NSCLC Recruiting 
1 Plus pembrolizumab  
Locally advance or 
metastatic NSCLC 
Recruiting  
2 Monotherapy Limited disease SCLC Not yet open 
2 
Plus carboplatin and 
etoposide 
Extensive disease 
SCLC 
Recruiting 
3 
Plus etoposide and 
platinum therapy 
Newly diagnosed 
extensive disease SCLC 
Recruiting 
3 
Plus paclitaxel and 
carboplatin 
Squamous NSCLC Recruiting  
MPDL3280A1 
1b Plus Tarceva NSCLC Not yet open 
2 Monotherapy  
PDL-1+ locally 
advanced NSCLC 
Recruiting 
2 Plus docetaxel 
Locally/advanced 
disease post-platinum 
NSCLC 
Recruiting  
3 Monotherapy  
Locally/advanced 
disease post-platinum 
NSCLC 
Recruiting  
Tremelimumab 
1 Plus gefitinib NSCLC Recruiting 
1b Plus MED14763 Advanced NSCLC Recruiting 
www.clinicaltrials.gov, accessed 26 March 2014 * And not recruiting 
Implications of the adaptive immune resistane 
mechanism for combinatorial immunotherapy of cancer  
Pardoll DM. Nature Rev Cancer 12:252-264, 2012 
Will immunotherapy obsolete CT/targeted therapy? 
No – CT/targeted therapy primes tumour immunity 
Magnitude of genomic derangement 
?? 
Lawrence MS, et al. Nature 499: 214-218, 2013 
Tumours with increased mutations are more likely to have increased T cells 
Immunotherapy – The beginning of the end for cancer 
 
Transforming cancer into chronic disease 
―Immunotherapies wil likely become the treatment backbone in up 
60% of cancers over the next 10 years compared with < 3% today.‖ 
Andrew Baum, MD 
Champiat S, et al. J Thorac Oncol 9:144-153, 2014 
Open questions 
→ Anti-PD1 vs anti-PD-L1 (schedule) 
 
→ Augment the efficacy (combination therapy, sequencing, maintenance) 
 
→ Combination therapy (CT, targeted agents, immunotherapy) 
 
→ Duration of therapy (1 year, 2 years, indefinitely) 
 
→ Toxicity (pneumonitis) 
 
→ Treat beyond progression 
 
→ What to do after acquired resistance 
 
→ PD-L1 as a predictive biomarker or other biomarkers 
  
 
Summary 
→ Anti-tumour immune response through vaccination is appealing, but 
achieving objective response is quite rare. 
 Nevertheless cancer vaccines remain a valid treatment that need further 
development 
 New formulations/vaccine vectors, new antigens and application together with 
checkpoint blockade will likely rejuvenate cancer vaccine strategies 
 
→ Immune-checkpoint blockade (CTLA-4, PD-1, PG-L1 antibodies) has 
demonstrated clear evidence of objective responses and survival. 
 Probably and like several trials are seeking, we will need to combine 
conventional therapy with immune checkpoint blockade 
 Unanswered safety and efficacy questions 
 
→ Immunotherapies and combination immunotherapies will be the wave of the 
future. 
 Key: improve responses 
 
pelo doente, 
para o doente 
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www.pulmonale.pt 
